Lexicon Pharmaceuticals has reported that LX4211, an inhibitor of the sodium-dependent glucose transporter 2 (SGLT2; also known as SLC5A2), significantly improved glycaemic control in a Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback